REGENXBIO

REGENXBIO is a clinical-stage biotechnology company based in Rockville, Maryland, founded in 2008. The company focuses on developing gene therapy technologies aimed at improving lives by addressing genetic defects. Its proprietary NAV Technology Platform utilizes recombinant adeno-associated virus (AAV) vectors to deliver genes to cells, potentially altering the course of various diseases. The company has a diverse product pipeline that includes treatments for retinal, metabolic, and neurodegenerative diseases. In addition to its internal development efforts, REGENXBIO licenses its NAV Vectors to other biotechnology companies, enhancing the reach and impact of its gene therapy solutions. Through strategic partnerships with key players in the biopharmaceutical industry, REGENXBIO leverages expertise to drive innovation and accelerate the development of its therapies. The company is dedicated to advancing gene therapy and bringing effective treatments to patients.